NCT05797168 2026-03-02
FONTANA
AstraZeneca
Phase 1/2 Recruiting
Clinical Trials
3 trialsNCT05266846 2024-05-30
BEYOND
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05503667 2022-08-17
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting